Location Factors for Cell and Gene Therapy Companies
The rise of cell and gene therapy (CGT) demands a strong supply chain, manufacturing operations, and specialized talent.
Q4 2021
Presently, there are approximately 900 companies worldwide focused on these advanced therapies, and over 1,000 cell and/or gene therapy clinical trials currently under way. A rise in the clinical pipeline, coupled with a rising number of regulatory approvals for advanced therapies, has significantly driven the market.
The global cell and gene therapy manufacturing market size is expected to reach $57.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is estimated to expand at a compound annual growth rate (CAGR) of 20.3 percent from 2021 to 2028.
Traditional supply chain models will not effectively meet the needs of these companies that are producing personalized therapies that must quickly and efficiently be delivered to their customers and patients. Supply chains that support the manufacturing and delivery of cell and gene therapies are long, complex, and highly controlled. As such, companies across the globe are looking to the United States to find locations with a thriving innovation ecosystem and a strong mix of a highly skilled workforce, robust supply chains, and manufacturing centers to meet their growing needs.
The global cell and gene therapy manufacturing market size is expected to reach $57.4 billion by 2028. Ideal Location Factors for CGT Companies
Ability to hire specialized talent: The cell and gene therapy industry is growing rapidly and there is deepening demand for a highly educated, highly trained workforce. Cell and gene therapy manufacturing is a complex, largely manual process that requires numerous skilled employees in an extremely monitored environment. Markets with a large pharmaceutical footprint are often the most appealing, as manufacturers can utilize the talent pool from industries where traditional, chemical-based medicines are made, or markets where other regulated industries manufacturing products for human consumption, like cosmetics and nutraceuticals, are based.
To address workforce needs, the New Jersey Institute of Technology (NJIT), in collaboration with New Jersey Innovation Institute (NJII) is offering a professional science master’s degree program and professional graduate certificate in cell and gene therapy — the only one of its kind in the United States. In addition, NJII developed a cutting-edge apprenticeship program where select students are trained for the field of bio-manufacturing over an 18-month period.
Proximity to robust transportation systems: The highly specialized manufacturing process required for cell and gene therapy imposes significant burdens due to the complexities associated with transporting, storing, and processing raw materials and shipping finished products. The production of cell therapies requires even greater vigilance against threats that can degrade purity, potency, and efficacy.
To date, the majority of cell and gene manufacturing companies are located in the northeast United States. The highly connected, affluent, and concentrated Boston–New York City–Philadelphia–Washington, D.C., markets offer logistical supply chain solutions for cell and gene therapy companies that need to move drug products quickly. The East Coast’s vast transportation system can easily expedite express deliveries to maintain the integrity of cell and gene therapies, and access to transportation systems make it easy to move products across the country or around the world.
Markets with a large pharmaceutical footprint are often the most appealing. Cluster of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research
Organizations (CROs): Cell and gene therapy developers benefit from cities and regions featuring a “cluster” of CDMOs and CROs to move “from bench to bedside.” CDMOs help companies translate a drug into scalable, commercialized treatment, while CROs manage clinical trials. As many CDMOs in Europe have been booked since COVID-19, this presents a unique opportunity for the United States to attract international companies to establish their operations here.
A supportive ecosystem where innovation thrives: As cell and gene therapy developers are struggling with global constraints, there are a number of markets across the United States that offer a supportive ecosystem for these developers to thrive. Cell and gene therapy companies succeed when they can tap into an innovation ecosystem that includes incubators and accelerators, research parks and hubs, and the ability to partner with research universities, medical schools, and hospitals. Much of the initial stage research is happening in Boston, and companies that are further along in product development have turned their focus to the New York-New Jersey area.
The production of cell therapies requires even greater vigilance against threats that can degrade purity, potency, and efficacy. Looking Ahead
Cell and gene therapy, while still a burgeoning industry, presents a real opportunity for future economic growth for select markets across the country. Despite significant disruptions in the supply chain caused by the COVID-19 pandemic, cell and gene therapy R&D and commercialization continued to accelerate in the marketplace. As we look ahead, the U.S. market should be focused on ways to attract, support, and retain cell and gene therapy companies, which will ultimately drive investment, employment, and — most importantly — save lives.
Project Announcements
Japan-Based Armada Nutrition Expands Spring Hill, Tennessee, Production Operations
02/18/2024
Enable Injections Plans Springdale, Ohio, Manufacturing Operations
02/15/2024
QuidelOrtho Upgrades Athens County, Ohio, Operations
02/13/2024
British-Based AstraZeneca Plans Rockville, Maryland, Manufacturing Operations
02/07/2024
Compact Membrane Systems Expands New Castle, Delaware, Operations
02/02/2024
Cellares Plans Bridgewater, New Jersey, Production Operations
01/30/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
The Logistics Analysis That Drives Industrial Site Selection
Q4 2023
-
2023 Top States Commentary: Top-Ranked States Have What It Takes to Win Mega Projects
Q3 2023
-
Technology’s Influence on Workforce Development
Workforce Q4 2023
-
AI 101 for Site Selection
Q4 2023
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023